{"prompt": "['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', 'months after the last dose of study treatment. Men must refrain from donating', 'sperm during this same period.', 'With pregnant female partners, men must remain abstinent or use a condom', 'during the treatment period and for 6 months after the last dose of study', 'medication to avoid exposing the embryo.', 'Exclusion', '1.', 'Treatment of metastases greater than 3 cm with radio-frequency/microwave', 'criteria', 'ablation within 24 months prior to study entry if applicable.', '2.', 'Treatment of metastases greater than 5 cm with radiation (stereotactic/', 'brachytherapy) within 24 months prior to study entry if applicable.', '3.', 'Previous chemotherapy for metastatic or localized disease with > 6 cycles of', 'FOLFOX (or FOLFOXIRI) or > 4 cycles of CAPOX/XELOX.', '4.', 'New York Heart Association Class III or greater heart failure by clinical', 'judgement.', '5. Myocardial infarction within 6 months prior to randomization; percutaneous', 'transluminal coronary angioplasty (PTCA) with or without stenting within 6', 'months prior to randomization.', '6.', 'Unstable angina pectoris.', '7. Unstable cardiac arrhythmia > grade 2 NCI CTCAE despite anti-arrhythmic', 'therapy.', '8. Ongoing toxicities > grade 2 NCI CTCAE, in particular peripheral neuropathy.', \"9. Active uncontrolled infection by investigator's perspective.\", '10. Severe chronic non-healing wounds, ulcerous lesions or untreated bone', 'fracture.', '11. Known hypersensitivity to 5-FU, leucovorin, irinotecan or oxaliplatin or to any of', 'the other excipients listed in section 6.1 of the corresponding SmPC.', '12. Bone marrow depression after radio- or chemotherapy.', '13. Severe kidney dysfunction (creatinine clearance < 30 ml/min) or changes in', 'blood count.', '14. Recent or concomitant treatment with brivudine.', '15. Peripheral sensitive neuropathy with functional impairment (> grade 1 acc. to', 'CTCAE version 5.0 (see appendix)).', '16. Inflammatory bowel disease and/or bowel obstruction.', '17. Simultaneous application of Johannis herbs preparations.', '18. Pernicious or other megaloblastic anaemia caused by vitamin B12 deficiency.', '19. If tested, DPD deficiency test with a CPIC activity score <1.', '20. Major surgical procedure, open biopsy, or significant traumatic injury within 21', 'days prior to randomization, or abdominal surgery, abdominal interventions or', 'significant abdominal traumatic injury within 21 days prior to randomization or', 'anticipation of need for major surgical procedure during the course of the study', 'or non-recovery from side effects of any such procedure.', '21.', 'Any other disease, metabolic dysfunction, physical examination finding, or', 'clinical laboratory finding that contraindicates the use of an investigational drug,', 'may affect the interpretation of the results, or may render the patient at high risk', 'from treatment complications.', '22. Medical history of malignant disease other than mCRC with the following', 'exceptions:', '-', 'patients who have been disease-free for at least three years before', 'randomization', 'Confidential', 'Page 16 of 79']['Charit\u00e9 Universit\u00e4tsmedizin Berlin', 'Prof. Dr. med. Dominik Modest', 'FIRE-9 PORT', '28-Sep-2021', 'EudraCT no. 2020-006144-18', 'Protocol Version 3.0', '-', 'patients with adequately treated and completely resected basal cell or', 'squamous cell skin cancer, in situ cervical, breast or prostate cancer, stage', 'I uterine cancer', '-', 'patients with any treated or untreated malignant disease that is associated', 'with a 5-year survival prognosis of 90% and does not require active', 'therapy', '23. Known alcohol or drug abuse.', '24. Pregnant or breastfeeding females.', '25. Participation in a clinical trial or experimental drug treatment within 28 days prior', 'to potential inclusion in the clinical trial or within a period of 5 half-lives of the', 'substances administered in a clinical trial or during an experimental drug', 'treatment prior to potential inclusion in the clinical trial, depending on which', 'period is longest, or simultaneous participation in another clinical trial while', 'taking part in this clinical trial.', '26. Patients depended on Sponsor, investigator or study site.', '27. Suspected SARS-CoV-2 infection with or without symptoms (evaluation', 'according to local policy in respective center with respect to actual status of', 'pandemic and with reference to the policy that would apply to patients with', 'similar therapy outside the trial). This may include assessment of vaccination', 'status, anamnesis, physical examination and potentially antigen and/or PCR', 'testing.', '28. Patient committed to an institution by virtue of an order issued either by the', 'judicial or the administrative authorities.', '29. Limited legal capacity.', 'Treatment,', 'Arm A:', 'dosage and', '14-day cycle (q14d), choice of (by stratification) intravenous therapy for up to', 'administration', '12 cycles*:', 'mFOLFOXIRI: Oxaliplatin 85 mg/m\u00b2 2h day 1, Irinotecan 150 mg/m\u00b2 90min day 1,', 'Leucovorin 400 mg/m\u00b2 1-2h day 1, followed by 5-FU 2400 mg/m\u00b2 46h.', 'or', 'mFOLFOX-6: Oxaliplatin 85 mg/m\u00b2 2h day 1, Leucovorin 400 mg/m\u00b2 1-2h day 1,', '5-FU 400 mg/m\u00b2 bolus**, followed by 5-FU 2400 mg/m\u00b2 46h.', '*NOTE: Both regimens should be adjusted individually for the total dose of oxaliplatin, i.e. a', 'maximum of 12 cycles taking neoadjuvant therapy any other treatment prior to the planed', 'trial intervention into account. Thus, for patients pre-treated with q14d FOLFOX(IRI) or q21d', 'CAPOX/XELOX, the trial intervention should be adjusted by a de-escalation to FOLFIRI or', 'further to fluoropyrimidine monotherapy (following FOLFOXIRI) or to single-agent', 'fluoropyrimidine (following FOLFOX) to allow for a total trial intervention duration of 6 months', '(see Section 5.2.3.1 for details).', '**5-FU 400 mg/m\u00b2 bolus can be used according to site specific routine.', 'Further de-escalations and dose modifications are allowed per institutional', 'standard as investigators decision.', 'The treatment is continued in Arm A for a maximum of 12 cycles or until', 'relapse/progression according to the local investigator or unacceptable toxicity', 'whatever comes first.', 'Confidential', 'Page 17 of 79']\n\n###\n\n", "completion": "END"}